PMID- 16420437
OWN - NLM
STAT- MEDLINE
DCOM- 20060406
LR  - 20161124
IS  - 0953-816X (Print)
IS  - 0953-816X (Linking)
VI  - 23
IP  - 1
DP  - 2006 Jan
TI  - Decrease in parvalbumin-expressing neurons in the hippocampus and increased 
      phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) 
      model of schizophrenia.
PG  - 279-84
AB  - Treatment of rats with methylazoxymethanol (MAM) on gestational day (GD)17 
      disrupts corticolimbic development in the offspring (MAM-GD17 rats) and leads to 
      abnormalities in adult MAM-GD17 rats resembling those described in schizophrenic 
      patients. The underlying changes in specific cortical and limbic cell populations 
      remain to be characterised. In schizophrenia, decreases in inhibitory 
      gamma-aminobutyric acid (GABA)-containing interneurons that express the 
      calcium-binding protein parvalbumin have been reported in the prefrontal cortex 
      and hippocampus. In this study we analysed the expression of parvalbumin (PV), 
      calretinin (CR) and calbindin (CB) in the prefrontal cortex and hippocampus of 
      MAM-GD17 rats. Exposure in utero to MAM led to a significant decrease in the 
      number of neurons expressing PV in the hippocampus, but not the prefrontal 
      cortex. Neurons expressing CR or CB were not affected in either structure. The 
      neurochemical changes in MAM-GD17 rats were accompagnied by increased 
      hyperlocomotion after administration of phencyclidine (PCP), analogous to the 
      hypersensitivity of schizophrenic patients to PCP. Therefore, the developmental 
      MAM-GD17 model reproduces key neurochemical and behavioural features that reflect 
      cortical and subcortical dysfunction in schizophrenia, and could be a useful tool 
      in the development of new antipsychotic drugs.
FAU - Penschuck, Silke
AU  - Penschuck S
AD  - Department of Neuroscience, 900, Lundbeck Research USA, Inc., 215 College Road, 
      Paramus, NJ 07652-1431, USA. SILP@lundbeck.com
FAU - Flagstad, Peter
AU  - Flagstad P
FAU - Didriksen, Michael
AU  - Didriksen M
FAU - Leist, Marcel
AU  - Leist M
FAU - Michael-Titus, Adina T
AU  - Michael-Titus AT
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Parvalbumins)
RN  - 592-62-1 (Methylazoxymethanol Acetate)
RN  - J1DOI7UV76 (Phencyclidine)
RN  - JGG19N3YDQ (methylazoxymethanol)
SB  - IM
MH  - Analysis of Variance
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Cell Count/methods
MH  - Disease Models, Animal
MH  - Embryo, Mammalian
MH  - Excitatory Amino Acid Antagonists/*pharmacology
MH  - Female
MH  - Gene Expression/drug effects
MH  - Hippocampus/drug effects/*pathology
MH  - Immunohistochemistry/methods
MH  - Methylazoxymethanol Acetate/*analogs & derivatives
MH  - Motor Activity/*drug effects
MH  - Neurons/drug effects/*metabolism
MH  - Parvalbumins/*metabolism
MH  - Phencyclidine/*pharmacology
MH  - Prefrontal Cortex/drug effects/pathology
MH  - Pregnancy
MH  - Prenatal Exposure Delayed Effects
MH  - Rats
MH  - Rats, Wistar
MH  - *Schizophrenia/chemically induced/metabolism/physiopathology
MH  - Time Factors
EDAT- 2006/01/20 09:00
MHDA- 2006/04/07 09:00
CRDT- 2006/01/20 09:00
PHST- 2006/01/20 09:00 [pubmed]
PHST- 2006/04/07 09:00 [medline]
PHST- 2006/01/20 09:00 [entrez]
AID - EJN4536 [pii]
AID - 10.1111/j.1460-9568.2005.04536.x [doi]
PST - ppublish
SO  - Eur J Neurosci. 2006 Jan;23(1):279-84. doi: 10.1111/j.1460-9568.2005.04536.x.